Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

Table 4 Prior chemotherapy agents before EGFR and FGFR inhibitor therapy in affected patients

	Case	Drug	Sex	Age	Diagnosis	Prior chemotherapy agents before study drugs
EGFR inhibitor (Tyrosine Kinase Inhibitor)	1	Vandetanib	2	30–39	NSCLC	Doxorubicin, Cisplatin, Pemetrexed, Geftinib, Gemcitabine
	2		2	60–69	NSCLC	Doxorubicin, cisplatin
	3		2	70–79	NSCLC	Gemcitabine, cisplatin
	4	Osimertinib	2	50–59	NSCLC	Afatinib
	5	ABT-414	1	50–59	Glioblastoma	Temozolomide
	6		2	70–79	Glioblastoma	Temozolomide
	7		2	50–59	Glioblastoma	Temozolomide
	8		1	40–49	Glioblastoma	Temozolomide
	9		2	60–69	Glioblastoma	none
FGFR inhibitor	10	ASP5878	2	40–49	HCC	Sorafenib, Ramucirumab, Everolimus
	11	FPA144	2	40–49	Gastric cancer	Capecitabine, Oxaliplatin, Paclitaxel, Doxorubicin, Cisplatin, Irinotecan
	12	FPA144	2	60–69	Gastric cancer	Gemcitabine, Cisplatin, Doxorubicin, Capecitabine, Oxaliplatin

EGFR epidermal growth factor receptor, FGFR fibroblast growth factor receptor, NSCLC Non-small cell lung cancer, HCC Hepatocellular carcinoma

ISSN: 1471-2415